retatrutide research What is Peptide Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

Here's What To Know You may have heard of Ozempic, and other GLP-1 drugs

Patients with obesity, particularly when affected by cardiovascular and renal comorbidities in the context of CKM, may represent an ideal target population

You are not a candidate for GLP-1 medications through our program if you are, or have a history of: Pancreatitis Thyroid cancer or multiple endocrine neoplasia syndrome (whether yourself or a first-degree relative) Currently pregnant or trying to become pregnant Crohns disease Gastroparesis, or have had a gastric bypass, gastric band, or gastric sleeve surgery Your safety is our top priority, and we carefully evaluate all patients to ensure the best treatment plan

For more information about Keystone Infectious Diseases, click here.